Veli-Pekka Harjola is an Associate Chief Physician and cardiologist at the Medical ICU, Division of Emergency Care, Helsinki University Central Hospital, Finland. Dr Harjola has been investigator in several heart failure trials including 8 studies on both intravenous and oral levosimendan since 1996, including LIDO, SURVIVE and PERSIST. He is the present chairman of the working group for heart failure of Finnish Cardiac Society and a member of the working group of Acute Cardiac care in ESC and member of the European Heart Failure Association. His research interests include the management and prognostic factors of acute heart failure and he has 18 international publications. Dr Harjola is the primary investigator of the FINN-AKVA National Acute Heart Failure Study in Finland which includes 620 patients from 14 Finnish hospitals. He is also member of the expert committee of the Euro Heart Failure Survey II.